trending Market Intelligence /marketintelligence/en/news-insights/trending/rhPvQK399l52rzt3mmVZ4Q2 content esgSubNav
In This List

Teva releases EpiPen copycat for young children in the US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Teva releases EpiPen copycat for young children in the US

Teva Pharmaceutical Industries Ltd. said it released the generic version of Mylan NV's emergency allergy therapy EpiPen in the U.S. for use in young children.

The Israel-based generics drugmaker said the drug is available at most retail pharmacies in the U.S with a price tag of $300 for a pack of two automatic injector devices pre-filled with 0.15 milligrams of epinephrine. The other version of the auto-injectors, containing 0.30 mg of epinephrine, is for use in patients weighing more than 66 pounds, while the smaller dose is for use in patients weighing about 33 to 66 pounds.

Teva is already selling the copycat version of the treatment for adults in the U.S. after receiving regulatory approval in August 2018. That version is priced at $300 per two-pack by Teva, matching the price of Mylan's own copycat of the treatment.

Canonsburg, Pa.-based Mylan launched the generic version of its EpiPen in late 2016, and came under fire from lawmakers and regulators in the U.S. when the price for EpiPen increased six-fold to about $600. The drug has consistently been pointed to as a flash-point in the national debate around drug pricing.